Ozempic Face 2026: Why Dermatologists Are Treating Facial Aging at Record Rates

# Ozempic Face 2026: Why Dermatologists Are Treating Facial Aging at Record Rates

> **Quick answer:** "Ozempic face" is the rapid facial aging that occurs when GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) cause fast, significant fat loss. Hollow cheeks, sagging skin, and deepened wrinkles are the hallmarks. A 2025 systematic review found patients can appear up to 5 years older — and dermatologists in 2026 are fielding more treatment requests than ever before, ranging from hyaluronic acid fillers to radiofrequency microneedling. The good news: most cases are preventable and treatable.

Ozempic face 2026 has officially become a dermatology crisis. Roughly 32 million Americans — about 13% of the adult population — have now used a GLP-1 receptor agonist, and a growing number of them are walking into dermatology offices with the same complaint: they lost the weight, but they also lost their face.

## What Is "Ozempic Face" — and What's Actually Happening Under the Skin

The term was coined by New York dermatologist Dr. Paul Jarrod Frank to describe an unmistakable cluster of changes: sunken temples, hollowed cheeks, prominent tear troughs, sagging jowls, and nasolabial folds that seem to have aged a decade overnight.

A landmark systematic review published in 2025 in PMC — analyzing 23 studies, 96% of them published between 2023 and 2025 — confirmed what practitioners were already seeing in their offices. Patients who lost 14.9% of their body weight over 68 weeks on GLP-1 therapy (versus 2.4% on placebo) experienced measurable facial volume loss that left them appearing "up to 5 years older than peers."